\uff5e ³Ô¹Ï±¬ÁÏ Digital Trials Platform\u306f\u30b9\u30c6\u30fc\u30af\u30db\u30eb\u30c0\u30fc\u9593\u306b\u304a\u3051\u308b<\/p>\n
\u30b7\u30fc\u30e0\u30ec\u30b9\u306a\u81e8\u5e8a\u8a66\u9a13\u306e\u5b9f\u65bd\u3068\u30c7\u30fc\u30bf\u30d5\u30ed\u30fc\u3092\u5b9f\u73fe<\/p>\n
\u60a3\u8005\u4e2d\u5fc3\u306e\u81e8\u5e8a\u8a66\u9a13\u306b\u5411\u3051\u3066\u696d\u754c\u3092\u524d\u9032\u3055\u305b\u308b\u65b0\u6a5f\u80fd\u3092\u642d\u8f09 \uff5e<\/p>\n
<\/p>\n
2021\u5e7410\u670821\u65e5<\/p>\n
³Ô¹Ï±¬ÁÏ Japan\u682a\u5f0f\u4f1a\u793e<\/p>\n
<\/p>\n
³Ô¹Ï±¬ÁÏ Systems\u3010NYSE:VEEV\u3011(\u672c\u793e : \u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5dde\u30d7\u30ec\u30b6\u30f3\u30c8\u30f3\u3001\u65e5\u672c\u6cd5\u4eba \u672c\u793e : \u6771\u4eac\u90fd\u6e0b\u8c37\u533a\u3001\u65e5\u672c\u6cd5\u4eba\u4ee3\u8868\u53d6\u7de0\u5f79 : \u5ca1\u6751 \u5d07\u3001\u4ee5\u4e0b ³Ô¹Ï±¬ÁÏ) \u306f\u3001\u88ab\u9a13\u8005\u3001\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u3001\u30b9\u30dd\u30f3\u30b5\u30fc\u3092\u3064\u306a\u3050\u5b8c\u5168\u306a\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u30a8\u30b3\u30b7\u30b9\u30c6\u30e0\u3092\u63d0\u4f9b\u3059\u308b\u3053\u3068\u306b\u3088\u3063\u3066\u81e8\u5e8a\u8a66\u9a13\u306e\u5b9f\u65bd\u3092\u5927\u5e45\u306b\u8fc5\u901f\u5316\u3059\u308b\u65b0\u3057\u3044\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u300c³Ô¹Ï±¬ÁÏ Digital Trials Platform\u300d\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002³Ô¹Ï±¬ÁÏ Digital Trials Platform\u306f\u73fe\u5728\u3001\u30a2\u30fc\u30ea\u30fc\u30a2\u30c0\u30d7\u30bf\u30fc\u306b\u63d0\u4f9b\u4e2d\u3067\u3059\u3002 (\u672c\u30ea\u30ea\u30fc\u30b9\u306f\u3001³Ô¹Ï±¬ÁÏ\u7c73\u56fd\u672c\u793e\u304c\u767a\u8868\u3057\u305f\u5831\u9053\u8cc7\u6599\u306e\u6284\u8a33\u3067\u3059\u3002\u539f\u6587\u306f\u3053\u3061\u3089<\/a><\/strong>\u304b\u3089\u304a\u8aad\u307f\u3044\u305f\u3060\u3051\u307e\u3059\u3002)<\/p>\n <\/p>\n \u3053\u306e\u5305\u62ec\u7684\u306a\u88fd\u54c1\u7fa4\u306f\u3001\u6b21\u306e\u30b3\u30a2\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u3067\u69cb\u6210\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n \u3044\u305a\u308c\u306e\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u3082\u3001\u88ab\u9a13\u8005\u3001\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u3001\u30b9\u30dd\u30f3\u30b5\u30fc\u56fa\u6709\u306e\u30cb\u30fc\u30ba\u306b\u5408\u308f\u305b\u3066\u8a2d\u8a08\u3055\u308c\u3066\u3044\u307e\u3059\u304c\u3001\u3059\u3079\u3066\u306e\u30b9\u30c6\u30fc\u30af\u30db\u30eb\u30c0\u30fc\u9593\u3067\u306e\u30b7\u30fc\u30e0\u30ec\u30b9\u306a\u8a66\u9a13\u5b9f\u65bd\u3068\u30c7\u30fc\u30bf\u30d5\u30ed\u30fc\u3092\u5b9f\u73fe\u3059\u308b\u63a5\u7d9a\u6027\u3092\u5099\u3048\u3066\u3044\u307e\u3059\u3002<\/p>\n \u88ab\u9a13\u8005\u304b\u3089\u306e\u540c\u610f\u53d6\u5f97\u30d7\u30ed\u30bb\u30b9\u306f\u3001³Ô¹Ï±¬ÁÏ Digital Trials Platform\u304c\u30b3\u30e9\u30dc\u30ec\u30fc\u30b7\u30e7\u30f3\u3068\u30c7\u30fc\u30bf\u30d5\u30ed\u30fc\u3092\u3069\u3046\u4fc3\u9032\u3059\u308b\u306e\u304b\u3092\u793a\u3059\u597d\u4f8b\u3067\u3059\u3002\u30b9\u30dd\u30f3\u30b5\u30fc\u304c³Ô¹Ï±¬ÁÏ eConsent\u3092\u4f7f\u7528\u3057\u3066\u540c\u610f\u30d5\u30a9\u30fc\u30e0\u3092\u4f5c\u6210\u3057\u3001\u627f\u8a8d\u3059\u308b\u3068\u3001³Ô¹Ï±¬ÁÏ SiteVault Free\u3092\u4f7f\u7528\u3057\u3066\u3044\u308b\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u306b\u81ea\u52d5\u7684\u306b\u9001\u4fe1\u3055\u308c\u307e\u3059\u3002\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u306f\u53d7\u4fe1\u3057\u305f\u540c\u610f\u30d5\u30a9\u30fc\u30e0\u3092\u9069\u5b9c\u5909\u66f4\u3057\u3001IRB\u306e\u627f\u8a8d\u3092\u5f97\u305f\u3046\u3048\u3067\u3001My³Ô¹Ï±¬ÁÏ\u30e2\u30d0\u30a4\u30eb\u30a2\u30d7\u30ea\u30b1\u30fc\u30b7\u30e7\u30f3\u3092\u4f7f\u7528\u3057\u3066\u88ab\u9a13\u8005\u304b\u3089\u306e\u540c\u610f\u3092\u53d6\u5f97\u3057\u307e\u3059\u3002\u88ab\u9a13\u8005\u30b9\u30c6\u30fc\u30bf\u30b9\u3068\u540c\u610f\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u30d0\u30ea\u30c7\u30fc\u30b7\u30e7\u30f3\u6e08\u307f\u304b\u3064\u30b9\u30dd\u30f3\u30b5\u30fc\u306b\u5831\u544a\u53ef\u80fd\u306a\u30c7\u30fc\u30bf\u3068\u3057\u3066\u3001Vault Clinical Suite\u3067\u76f4\u3061\u306b\u5229\u7528\u3067\u304d\u308b\u72b6\u614b\u306b\u306a\u308a\u307e\u3059\u3002<\/p>\n ³Ô¹Ï±¬ÁÏ Digital Trials Platform\u306f\u3001\u5b8c\u5168\u304b\u3064\u6a19\u6e96\u5316\u3055\u308c\u305f\u9023\u643a\u6027\u306e\u3042\u308b\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u3092\u6c42\u3081\u308b\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u696d\u754c\u306e\u58f0\u306b\u5fdc\u3048\u308b\u3053\u3068\u306b\u3088\u308a\u3001\u30c7\u30fc\u30bf\u306e\u7cbe\u5ea6\u3068\u88ab\u9a13\u8005\u306e\u591a\u69d8\u6027\u3092\u5411\u4e0a\u3055\u305b\u3001\u81e8\u5e8a\u8a66\u9a13\u306e\u8fc5\u901f\u5316\u3068\u52b9\u7387\u5316\u3092\u5b9f\u73fe\u3057\u307e\u3059\u3002<\/p>\n ³Ô¹Ï±¬ÁÏ Vault R&D\u62c5\u5f53\u30f4\u30a1\u30a4\u30b9\u30d7\u30ec\u30b8\u30c7\u30f3\u30c8\u3067\u3042\u308bJim Reilly\u306f\u3001\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300c\u5f53\u793e\u306f\u3001³Ô¹Ï±¬ÁÏ SiteVault Free\u3092\u5229\u7528\u3059\u308b\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u306e\u9593\u3067\u62e1\u5927\u3059\u308b\u30b3\u30df\u30e5\u30cb\u30c6\u30a3\u3068\u3001Vault Clinical Suite\u3092\u5229\u7528\u3057\u3066\u3044\u308b\u30b9\u30dd\u30f3\u30b5\u30fc\u3092\u3064\u306a\u3050\u3053\u3068\u306b\u3088\u308a\u3001\u81e8\u5e8a\u8a66\u9a13\u5b9f\u65bd\u306e\u30c7\u30b8\u30bf\u30eb\u5316\u306e\u52d5\u304d\u3092\u52a0\u901f\u3055\u305b\u308b\u3053\u3068\u3092\u76ee\u6307\u3057\u3066\u3044\u307e\u3059\u3002³Ô¹Ï±¬ÁÏ Digital Trials Platform\u306b\u3088\u3063\u3066\u3001\u88ab\u9a13\u8005\u3001\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u3001\u30b9\u30dd\u30f3\u30b5\u30fc\u306b\u3068\u3063\u3066\u81e8\u5e8a\u8a66\u9a13\u304c\u3088\u308a\u5bb9\u6613\u306a\u3082\u306e\u3068\u306a\u308a\u3001\u8fc5\u901f\u5316\u3067\u304d\u308b\u3067\u3057\u3087\u3046\u3002\u300d<\/p>\n \u597d\u8abf\u306a\u51fa\u8db3\u3092\u898b\u305b\u308b<\/strong>³Ô¹Ï±¬ÁÏ Digital Trials<\/strong><\/p>\n \u696d\u754c\u521d\uff0a<\/sup>\u306e\u30c7\u30b8\u30bf\u30eb\u81e8\u5e8a\u8a66\u9a13\u30a2\u30d7\u30ea\u30b1\u30fc\u30b7\u30e7\u30f3\u3067\u3042\u308b³Ô¹Ï±¬ÁÏ Site Connect\u306f\u3001\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u3068\u30b9\u30dd\u30f3\u30b5\u30fc\u9593\u306e\u60c5\u5831\u5171\u6709\u3092\u624b\u4f5c\u696d\u306b\u3088\u308b\u7d19\u30d9\u30fc\u30b9\u306e\u3084\u308a\u3068\u308a\u304b\u3089\u3001\u81ea\u52d5\u5316\u3055\u308c\u305f\u30c7\u30b8\u30bf\u30eb\u306a\u4ea4\u63db\u30d7\u30ed\u30bb\u30b9\u3078\u3068\u5909\u9769\u3057\u307e\u3059\u3002\u73fe\u5728\u3001\u4e0a\u4f4d20\u793e\u306b\u5165\u308b\u88fd\u85ac\u5927\u624b\u3001\u30d0\u30a4\u30aa\u4f01\u696d\u3001\u305d\u3057\u3066Celerion\u793e\u306e\u3088\u3046\u306aCRO\u3092\u306f\u3058\u3081\u3001\u30a2\u30fc\u30ea\u30fc\u30a2\u30c0\u30d7\u30bf\u30fc\u306e\u30b9\u30dd\u30f3\u30b5\u30fc\u306b\u63a1\u7528\u3055\u308c\u3066\u3044\u307e\u3059\u3002 Celerion\u793e\u306e\u30a8\u30b0\u30bc\u30af\u30c6\u30a3\u30d6\u30c7\u30a3\u30ec\u30af\u30bf\u30fc\u3067\u3042\u308bJulie Saathoff\u6c0f\u306f\u3001\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300c³Ô¹Ï±¬ÁÏ Site Connect\u304a\u3088\u3073³Ô¹Ï±¬ÁÏ eConsent\u306e\u30a2\u30fc\u30ea\u30fc\u30a2\u30c0\u30d7\u30bf\u30fc\u3068\u3057\u3066³Ô¹Ï±¬ÁÏ\u3068\u306e\u30d1\u30fc\u30c8\u30ca\u30fc\u30b7\u30c3\u30d7\u3092\u5f37\u5316\u3055\u305b\u308b\u3053\u3068\u3067\u3001\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u3068\u88ab\u9a13\u8005\u306e\u4f53\u9a13\u3092\u5909\u9769\u3067\u304d\u308b\u3082\u306e\u3068\u671f\u5f85\u3057\u3066\u3044\u307e\u3059\u3002\u5f53\u793e\u306f\u5e74\u9593\u7d04200\u4ef6\u306e\u81e8\u5e8a\u8a66\u9a13\u3092\u5b9f\u65bd\u3057\u3066\u3044\u308b\u305f\u3081\u3001\u30b9\u30c6\u30fc\u30af\u30db\u30eb\u30c0\u30fc\u9593\u306e\u60c5\u5831\u30d5\u30ed\u30fc\u306e\u81ea\u52d5\u5316\u306f\u3001\u30aa\u30da\u30ec\u30fc\u30b7\u30e7\u30f3\u306e\u5927\u5e45\u306a\u30b9\u30ea\u30e0\u5316\u3001\u30b3\u30e9\u30dc\u30ec\u30fc\u30b7\u30e7\u30f3\u306e\u5f37\u5316\u3001\u30d7\u30ed\u30bb\u30b9\u306e\u8fc5\u901f\u5316\u306b\u5f79\u7acb\u3064\u3067\u3057\u3087\u3046\u3002\u307e\u305f\u3001\u52b9\u7387\u5316\u306b\u3088\u3063\u3066\u60a3\u8005\u30b1\u30a2\u306e\u6539\u5584\u3084\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u306e\u62e1\u5927\u3068\u8fc5\u901f\u5316\u306b\u3064\u306a\u304c\u308b\u3067\u3057\u3087\u3046\u3002\u300d<\/p>\n LEO Pharma\u793e\u306f\u5148\u9803\u3001³Ô¹Ï±¬ÁÏ Digital Trials Platform\u306e\u5168\u9762\u63a1\u7528\u306b\u5411\u3051\u305f³Ô¹Ï±¬ÁÏ\u3068\u306e\u30d1\u30fc\u30c8\u30ca\u30fc\u30b7\u30c3\u30d7\u3092\u767a\u8868<\/a><\/strong>\u3057\u307e\u3057\u305f\u3002³Ô¹Ï±¬ÁÏ Clinical Operations Suite\u306e\u5c0e\u5165\u6210\u529f\u3092\u8e0f\u307e\u3048\u3066\u3001\u65e2\u5b58\u306e³Ô¹Ï±¬ÁÏ\u81e8\u5e8a\u958b\u767a\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u306e\u6a19\u6e96\u5316\u3092\u5b8c\u4e86\u3055\u305b\u3001\u4eca\u5f8c\u767a\u8868\u3055\u308c\u308b³Ô¹Ï±¬ÁÏ\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u30a2\u30fc\u30ea\u30fc\u30a2\u30c0\u30d7\u30bf\u30fc\u3068\u3057\u3066\u3001³Ô¹Ï±¬ÁÏ\u306e\u30c7\u30b8\u30bf\u30eb\u81e8\u5e8a\u8a66\u9a13\u306e\u30ed\u30fc\u30c9\u30de\u30c3\u30d7\u5f62\u6210\u3092\u652f\u63f4\u3057\u307e\u3059\u3002<\/p>\n LEO Pharma\u793e\u306e\u30a8\u30b0\u30bc\u30af\u30c6\u30a3\u30d6\u30f4\u30a1\u30a4\u30b9\u30d7\u30ec\u30b8\u30c7\u30f3\u30c8\u517cR&D\u8cac\u4efb\u8005\u3067\u3042\u308bJ\u00f6rg M\u00f6ller\u6c0f\u306f\u3001\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300c\u5f53\u793e\u306f\u81e8\u5e8a\u8a66\u9a13\u3092\u5909\u9769\u3059\u308b\u65b9\u6cd5\u3092\u6a21\u7d22\u3057\u3066\u304d\u307e\u3057\u305f\u304c\u3001COVID-19\u3067\u305d\u306e\u9032\u5c55\u306b\u62cd\u8eca\u304c\u304b\u304b\u308a\u307e\u3057\u305f\u3002\u5909\u5316\u3092\u7d9a\u3051\u308b\u5e02\u5834\u306e\u52d5\u304d\u306b\u8fc5\u901f\u306b\u5bfe\u5fdc\u3059\u308b\u3053\u3068\u3067\u3001\u81e8\u5e8a\u8a66\u9a13\u3092\u9045\u6ede\u306a\u304f\u7d99\u7d9a\u3067\u304d\u307e\u3057\u305f\u3002³Ô¹Ï±¬ÁÏ\u3068\u306e\u63d0\u643a\u306f\u3001\u5f53\u793e\u306e2030\u5e74\u6226\u7565\u306e\u8ef8\u3068\u3057\u3066\u3001\u9769\u65b0\u7684\u306a\u6cbb\u7642\u6cd5\u3092\u60a3\u8005\u3055\u3093\u306b\u3088\u308a\u65e9\u304f\u5c4a\u3051\u308b\u3068\u540c\u6642\u306b\u30b5\u30b9\u30c6\u30ca\u30d6\u30eb\u306a\u4e8b\u696d\u3092\u7d99\u7d9a\u3059\u308b\u652f\u3048\u3068\u306a\u308b\u3067\u3057\u3087\u3046\u3002\u305d\u306e\u5b9f\u73fe\u306b\u306f\u3001\u5353\u8d8a\u3057\u305f\u88fd\u54c1\u5b9f\u7e3e\u306e\u3042\u308b³Ô¹Ï±¬ÁÏ\u306f\u9577\u671f\u306e\u30d1\u30fc\u30c8\u30ca\u30fc\u3068\u3057\u3066\u7406\u60f3\u7684\u3067\u3042\u308a\u3001\u60a3\u8005\u652f\u63f4\u3092\u3088\u308a\u65e9\u304f\u3088\u308a\u826f\u304f\u3067\u304d\u308b\u3088\u3046\u53d6\u308a\u7d44\u307f\u3092\u9032\u3081\u3066\u3044\u304f\u3053\u3068\u304c\u3067\u304d\u307e\u3059\u3002\u300d<\/p>\n <\/p>\n \u3010<\/strong>³Ô¹Ï±¬ÁÏ Systems<\/strong>\u793e\u306b\u3064\u3044\u3066\u3011<\/strong> \u3010Forward-looking Statements\u3011 \u88ab\u9a13\u8005\u3001\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u3001\u30b9\u30dd\u30f3\u30b5\u30fc\u3092\u3064\u306a\u3050\u5b8c\u5168\u306a\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u30a8\u30b3\u30b7\u30b9\u30c6\u30e0\u3092\u63d0\u4f9b\u3059\u308b\u3053\u3068\u306b\u3088\u3063\u3066\u81e8\u5e8a\u8a66\u9a13\u306e\u5b9f\u65bd\u3092\u5927\u5e45\u306b\u8fc5\u901f\u5316\u3059\u308b\u65b0\u3057\u3044\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u300c³Ô¹Ï±¬ÁÏ Digital Trials Platform\u300d\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002<\/p>\n","protected":false},"author":131,"featured_media":46368,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[322,341],"tags":[],"class_list":["post-46366","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","category-case-study"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/46366"}],"collection":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/comments?post=46366"}],"version-history":[{"count":7,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/46366\/revisions"}],"predecessor-version":[{"id":46473,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/46366\/revisions\/46473"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/media\/46368"}],"wp:attachment":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/media?parent=46366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/categories?post=46366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/tags?post=46366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n\uff0a\u5f53\u793e\u8abf\u3079<\/span><\/p>\n
\n³Ô¹Ï±¬ÁÏ Systems\u793e\u306f\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u5411\u3051\u306b\u30af\u30e9\u30a6\u30c9\u30d9\u30fc\u30b9\u306e\u30bd\u30d5\u30c8\u30a6\u30a7\u30a2\u3092\u63d0\u4f9b\u3059\u308b\u30ea\u30fc\u30c7\u30a3\u30f3\u30b0\u30ab\u30f3\u30d1\u30cb\u30fc\u3067\u3059\u3002\u4e16\u754c\u6700\u5927\u898f\u6a21\u306e\u88fd\u85ac\u4f1a\u793e\u304b\u3089\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u5206\u91ce\u306e\u65b0\u8208\u4f01\u696d\u307e\u3067\u30011,100\u793e\u3092\u8d85\u3048\u308b\u9867\u5ba2\u306b\u6280\u8853\u9769\u65b0\u3078\u306e\u53d6\u308a\u7d44\u307f\u3084\u5353\u8d8a\u3057\u305f\u88fd\u54c1\u529b\u306b\u3088\u3063\u3066\u3001\u304a\u5ba2\u69d8\u306e\u6210\u529f\u306b\u30b3\u30df\u30c3\u30c8\u3059\u308b\u69d8\u3005\u306a\u30b5\u30fc\u30d3\u30b9\u3092\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002\u30d1\u30d6\u30ea\u30c3\u30af\u30fb\u30d9\u30cd\u30d5\u30a3\u30c3\u30c8\u30fb\u30b3\u30fc\u30dd\u30ec\u30fc\u30b7\u30e7\u30f3\u4f01\u696d\u3068\u3057\u3066³Ô¹Ï±¬ÁÏ\u306f\u3001\u9867\u5ba2\u3084\u5f93\u696d\u54e1\u3001\u63d0\u643a\u4f01\u696d\u3001\u682a\u4e3b\u3001\u30b5\u30fc\u30d3\u30b9\u63d0\u4f9b\u696d\u754c\u3092\u542b\u3080\u3059\u3079\u3066\u306e\u30b9\u30c6\u30fc\u30af\u30db\u30eb\u30c0\u30fc\u306e\u5229\u76ca\u30d0\u30e9\u30f3\u30b9\u3092\u4fdd\u3064\u3053\u3068\u306b\u30b3\u30df\u30c3\u30c8\u3057\u307e\u3059\u3002\u8a73\u3057\u304f\u306f\u3001https:\/\/veeva.com\/jp\/<\/a>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/p>\n
\nThis release contains forward-looking statements, including the market demand for and acceptance of ³Ô¹Ï±¬ÁÏ\u2019s products and services, the results from use of ³Ô¹Ï±¬ÁÏ\u2019s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon ³Ô¹Ï±¬ÁÏ\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ³Ô¹Ï±¬ÁÏ\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ³Ô¹Ï±¬ÁÏ disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect ³Ô¹Ï±¬ÁÏ\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-Q for the period ended July 31, 2021.This is available on the company\u2019s website at veeva.com<\/a> under the Investors section and on the SEC\u2019s website at sec.gov<\/a>. Further information on potential risks that could affect actual results will be included in other filings ³Ô¹Ï±¬ÁÏ makes with the SEC from time to time.<\/p>\n","protected":false},"excerpt":{"rendered":"